B Charbonnel

Summary

Country: France

Publications

  1. ncbi request reprint Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes
    Khadija Ouguerram
    Centre de Recherche en Nutrition Humaine, INSERM U539 Hôtel Dieu, France
    J Pharmacol Exp Ther 306:332-7. 2003
  2. ncbi request reprint Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes
    B Charbonnel
    Endocrinology Clinic, Hotel Dieu, Place Alexis Ricordeau, 44093, Nantes Cedex 1, France
    Diabetologia 48:1093-104. 2005
  3. ncbi request reprint Glitazones in the treatment of diabetes mellitus: clinical outcomes in large scale clinical trials
    Bernard Charbonnel
    Department of Endocrinology and Diabetes, University Hospital, Nantes, France
    Fundam Clin Pharmacol 21:19-20. 2007
  4. ncbi request reprint [Metabolic syndrome and cardiovascular risk]
    Bernard Charbonnel
    Clinique d Endocrinologie, Maladies metaboliques et nutrition, hôpital de l Hôtel dieu, 44093 Nantes
    Rev Prat 55:1765-71. 2005
  5. doi request reprint Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19)
    Bernard Charbonnel
    Clinique d Endocrinologie, Maladies Metaboliques, et Nutrition, Centre Hospitalier Universitaire de Nantes, Hotel Dieu, 1, Place Alexis Ricordeau, 44093 Nantes Cedex 1, France
    J Clin Endocrinol Metab 95:2163-71. 2010
  6. ncbi request reprint [Is the metabolic syndrome still a useful entity?]
    Bernard Charbonnel
    Clinique d Endocrinologie, Maladies metaboliques et nutrition, Hotel Dieu, 44093 Nantes Cedex 1
    Rev Prat 60:478-84. 2010
  7. doi request reprint Pharmacological management of type 2 diabetes: the potential of incretin-based therapies
    B Charbonnel
    Department of Endocrinology and Diabetes, University Hospital, Nantes, France
    Diabetes Obes Metab 13:99-117. 2011
  8. ncbi request reprint In vivo evidence for the role of lipoprotein lipase activity in the regulation of apolipoprotein AI metabolism: a kinetic study in control subjects and patients with type II diabetes mellitus
    R Frenais
    Human Nutrition Research Center, INSERM, U 539, Hotel Dieu, 44093 Nantes Cedex 01, France
    J Clin Endocrinol Metab 86:1962-7. 2001
  9. ncbi request reprint Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens
    B Charbonnel
    Endocrinology Clinic, Hotel Dieu Hospital, Nantes, France
    Diabetologia 48:553-60. 2005
  10. doi request reprint Clinical and metabolic characteristics of patients with latent autoimmune diabetes in adults (LADA): absence of rapid beta-cell loss in patients with tight metabolic control
    L Chaillous
    Clinique d Endocrinologie, Maladies metaboliques et nutrition, Institut du Thorax, Hopital Laennec, Boulevard Jacques Monod, Nantes Cedex 1, France
    Diabetes Metab 36:64-70. 2010

Detail Information

Publications33

  1. ncbi request reprint Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes
    Khadija Ouguerram
    Centre de Recherche en Nutrition Humaine, INSERM U539 Hôtel Dieu, France
    J Pharmacol Exp Ther 306:332-7. 2003
    ..05). We concluded that atorvastatin improved lipid abnormalities in type-2 diabetic patients not only by increasing the clearance of apoB100-containing lipoproteins but also by decreasing VLDL production...
  2. ncbi request reprint Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes
    B Charbonnel
    Endocrinology Clinic, Hotel Dieu, Place Alexis Ricordeau, 44093, Nantes Cedex 1, France
    Diabetologia 48:1093-104. 2005
    ....
  3. ncbi request reprint Glitazones in the treatment of diabetes mellitus: clinical outcomes in large scale clinical trials
    Bernard Charbonnel
    Department of Endocrinology and Diabetes, University Hospital, Nantes, France
    Fundam Clin Pharmacol 21:19-20. 2007
    ..The other available data, published as meta-analyses, suggest that there is a difference in this regard between pioglitazone and rosiglitazone...
  4. ncbi request reprint [Metabolic syndrome and cardiovascular risk]
    Bernard Charbonnel
    Clinique d Endocrinologie, Maladies metaboliques et nutrition, hôpital de l Hôtel dieu, 44093 Nantes
    Rev Prat 55:1765-71. 2005
    ..Metabolic syndrome could become a target for some specific therapeutic interventions...
  5. doi request reprint Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19)
    Bernard Charbonnel
    Clinique d Endocrinologie, Maladies Metaboliques, et Nutrition, Centre Hospitalier Universitaire de Nantes, Hotel Dieu, 1, Place Alexis Ricordeau, 44093 Nantes Cedex 1, France
    J Clin Endocrinol Metab 95:2163-71. 2010
    ....
  6. ncbi request reprint [Is the metabolic syndrome still a useful entity?]
    Bernard Charbonnel
    Clinique d Endocrinologie, Maladies metaboliques et nutrition, Hotel Dieu, 44093 Nantes Cedex 1
    Rev Prat 60:478-84. 2010
    ..The visceral obesity, and insulin resistance associated with it, are the probable causes of a syndrome that has been "oversold"...
  7. doi request reprint Pharmacological management of type 2 diabetes: the potential of incretin-based therapies
    B Charbonnel
    Department of Endocrinology and Diabetes, University Hospital, Nantes, France
    Diabetes Obes Metab 13:99-117. 2011
    ..This review will examine current approaches for treating type 2 diabetes and discuss the place of incretin therapies, mainly GLP-1 agonists, in the type 2 diabetes treatment spectrum...
  8. ncbi request reprint In vivo evidence for the role of lipoprotein lipase activity in the regulation of apolipoprotein AI metabolism: a kinetic study in control subjects and patients with type II diabetes mellitus
    R Frenais
    Human Nutrition Research Center, INSERM, U 539, Hotel Dieu, 44093 Nantes Cedex 01, France
    J Clin Endocrinol Metab 86:1962-7. 2001
    ....
  9. ncbi request reprint Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens
    B Charbonnel
    Endocrinology Clinic, Hotel Dieu Hospital, Nantes, France
    Diabetologia 48:553-60. 2005
    ....
  10. doi request reprint Clinical and metabolic characteristics of patients with latent autoimmune diabetes in adults (LADA): absence of rapid beta-cell loss in patients with tight metabolic control
    L Chaillous
    Clinique d Endocrinologie, Maladies metaboliques et nutrition, Institut du Thorax, Hopital Laennec, Boulevard Jacques Monod, Nantes Cedex 1, France
    Diabetes Metab 36:64-70. 2010
    ..0+/-0.8% and 6.5+/-0.9%, respectively, at the time of entry into the study)...
  11. ncbi request reprint Which are the insulin treatment regimens used in France? The "Schema survey"
    B Charbonnel
    Clinique d Endocrinologie, Hotel Dieu, 44093 Nantes Cedex, France
    Diabetes Metab 27:591-7. 2001
    ..To examine how insulin therapy is used in France under real life conditions for type 1 and insulin-treated type 2 patients...
  12. ncbi request reprint Effect of low-density lipoproteins on apolipoprotein AI kinetics in heterozygous familial hypercholesterolemia
    R Frenais
    Centre de Recherche en Nutrition Humaine, Groupe Métabolisme, Hotel Dieu, Nantes, France
    Metabolism 50:635-9. 2001
    ..1 +/- 5.7 v 18.0 +/- 5.7 mg/kg/d, P <.05) after LDL-apheresis. These human kinetic data suggest that LDL do not play a major role on HDL production in heterozygous FH patients...
  13. ncbi request reprint [Present and future of insulin therapy in type 2 diabetic patients]
    B Charbonnel
    Service d endocrinologie, Hotel Dieu, 44093 Nantes
    Diabetes Metab 27:S15-22. 2001
    ..Glycaemic objectives (fasting blood glucose and HbA1c) should be regularly assessed and adapted taking into consideration diabetic control, clinical effects and safety assessments (weight gain, hypoglycaemic events...)...
  14. ncbi request reprint [New therapeutic approaches in diabetes]
    B Charbonnel
    Clinique d Endocrinologie Hôtel Dieu 44093 NANTES 1
    Ann Endocrinol (Paris) 64:352-3. 2003
  15. ncbi request reprint What a psychiatrist needs to know about diabetes
    B Charbonnel
    Clinique d Endocrinologie, Nantes Cedex, France
    Eur Psychiatry 20:S330-4. 2005
    ..The latter measure gives an indication of glycaemic control over a period of three months, and a reduction in glycosylated haemoglobin is the most appropriate treatment goal in the management of diabetes...
  16. ncbi request reprint The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients
    Bernard Charbonnel
    Clinique d Endocrinologie, Nantes Cedex, France
    Diabetes Care 27:1647-53. 2004
    ....
  17. doi request reprint Abdominal obesity is associated with ineffective control of cardiovascular risk factors in primary care in France
    J Dallongeville
    Service d Epidémiologie et Santé Publique, INSERM U744, Institut Pasteur de Lille, 1, rue du Professeur Calmette, 59019 Lille, France
    Diabetes Metab 34:606-11. 2008
    ..The goal of the present study was to evaluate the association of abdominal obesity with achievement of treatment targets for HbA(1c), LDL cholesterol, triglycerides, HDL cholesterol and blood pressure in primary care...
  18. doi request reprint Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical tri
    B Charbonnel
    University of Nantes, Nantes, France
    Diabetologia 56:1503-11. 2013
    ..The aim of this work was to compare treatment intensification strategies based on orally administered vs injectable incretin-based antihyperglycaemic agents in patients with type 2 diabetes mellitus on metformin monotherapy...
  19. doi request reprint Fulminant type 1 diabetes in Caucasians: A report of three cases
    C Moreau
    Clinique d Endocrinologie, Maladies metaboliques et nutrition, Institut du Thorax, CHU de Nantes, 44000 Nantes, France
    Diabetes Metab 34:529-32. 2008
    ..Until now, this subtype of type 1 diabetes has only been reported in the Asian population, especially Japanese and Koreans...
  20. doi request reprint Insulin therapy for diabetes mellitus: treatment regimens and associated costs
    B Charbonnel
    Service de Diabetologie, CHU de Nantes, Nantes Cedex 1, France
    Diabetes Metab 38:156-63. 2012
    ..To describe insulin therapy in patients with diabetes, to determine treatment costs and to compare costs among treatment regimens...
  21. ncbi request reprint Effect of dietary omega-3 fatty acids on high-density lipoprotein apolipoprotein AI kinetics in type II diabetes mellitus
    R Frenais
    Centre de Recherche en Nutrition Humaine, Groupe Métabolisme, INSERM U539, Hotel Dieu, Nantes, France
    Atherosclerosis 157:131-5. 2001
    ..05, and 12.1+/-2.8 vs. 16.1+/-3.3 mg/kg per day, P<0.05). These findings showed an effect of maxEPA(R) on kinetics of apolipoprotein AI in type II diabetes mellitus, probably linked to changes in plasma triglyceride level...
  22. ncbi request reprint Treatment of hypoglycemia using combined glucocorticoid and recombinant human growth hormone in a patient with a metastatic non-islet cell tumor hypoglycemia
    Nathalie Bourcigaux
    Endocrinology and Metabolism Service, Center University Hospital, Nantes, France
    Clin Ther 27:246-51. 2005
    ..However, in inoperable patients with NICTH, treatment of hypoglycemia may require high doses of glucocorticoid (30-60 mg/d [0.5-1.0 mg/kg x d]) or recombinant human GH (rhGH) (2.6-12.0 mg/d [0.043-0.20 mg/kg x d])...
  23. ncbi request reprint Type 2 diabetes management: putting theory into practice--introduction
    Bernard Charbonnel
    Centre Hospitalier Universitaire Hotel Dieu, Endocrinology, Metabolic and Nutrition Diseases, Nantes, France
    Metabolism 52:1-2. 2003
  24. ncbi request reprint Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma
    Eric Mirallie
    Clinique de Chirurgie Digestive et Endocrinienne, IMAD, Nantes, France
    Surgery 142:952-8; discussion 952-8. 2007
    ..The aim of this prospective study was to assess therapeutic impact of (18)FDG-PET imaging using a PET/computed tomography (CT) system in patients with iodine-negative recurrence of DTC...
  25. ncbi request reprint Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
    John A Dormandy
    Department of Clinical Vascular Research, Ingelby House, St Georges Hospital, Blackshaw Road, London SW17 0QT, UK
    Lancet 366:1279-89. 2005
    ..Our aim, therefore, was to ascertain whether pioglitazone reduces macrovascular morbidity and mortality in high-risk patients with type 2 diabetes...
  26. ncbi request reprint Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
    Bernard Charbonnel
    Center Hospitalier Universitaire de Nantes, France
    Diabetes Care 29:2638-43. 2006
    ....
  27. pmc PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study
    Erland Erdmann
    Department III of Internal Medicine, University of Cologne, Germany
    Vasc Health Risk Manag 3:355-70. 2007
    ..Here, we summarize the key results from the PROactive study and place them in context with other recent outcome trials in type 2 diabetes...
  28. ncbi request reprint Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08)
    Erland Erdmann
    Medizinische Klinik III der Universität zu Köln Kerpener Str 62, D 50937 Koln, Germany
    Diabetes Care 30:2773-8. 2007
    ..We analyzed the heart failure cases to assess the effects of treatment on morbidity and mortality after reports of serious heart failure...
  29. ncbi request reprint The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study
    Erland Erdmann
    Medizinische Klinik III der Universität zu Köln, Koln, Germany
    J Am Coll Cardiol 49:1772-80. 2007
    ....
  30. doi request reprint Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial
    Anne Katrin Sjølie
    Department of Ophthalmology, Odense University Hospital, Odense, Denmark
    Lancet 372:1385-93. 2008
    ..Diabetic retinopathy remains a leading cause of visual loss in people of working age. We examined whether candesartan treatment could slow the progression and, secondly, induce regression of retinopathy in people with type 2 diabetes...
  31. doi request reprint Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials
    Nish Chaturvedi
    International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College Healthcare NHS Trust, London, UK
    Lancet 372:1394-402. 2008
    ..We therefore designed the DIabetic REtinopathy Candesartan Trials (DIRECT) Programme to assess whether candesartan could reduce the incidence and progression of retinopathy in type 1 diabetes...
  32. ncbi request reprint Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus
    Paris Roach
    Department of Medicine, Indiana University School of Medicine, 545 Barnhill Drive, EH 421, Indianapolis, IN 46202, USA
    Clin Ther 26:502-10. 2004
    ..When used in a similar fashion, premixed, fixed-ratio insulin preparations containing LP and NPL (an LP-based intermediate-acting insulin) may provide the basis for an optimized basal-bolus insulin regimen...
  33. ncbi request reprint Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
    Lars Ryden
    Department of Cardiology, Karolinska University Hospital, Sweden
    Eur Heart J 28:88-136. 2007